{
  "paper_metadata": {
    "pmid": "37705003",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on the TTR gene variant A97S, including penetrance data and individual records."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.290C>T",
      "protein_notation": "p.Ala97Ser",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 14,
        "demographics": "Age: 62.1 \u00b1 4.9 years, Male: 93%",
        "phenotype": "Hereditary transthyretin cardiomyopathy (ATTR-CM)"
      },
      "penetrance_data": {
        "total_carriers_observed": 14,
        "affected_count": 11,
        "unaffected_count": 3,
        "uncertain_count": null,
        "penetrance_percentage": 78.57,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Cardiac involvement with heart failure symptoms.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Cardiac involvement with heart failure symptoms.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P3",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Cardiac involvement with heart failure symptoms.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P4",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Cardiac involvement with heart failure symptoms.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P5",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Cardiac involvement with heart failure symptoms.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P6",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Cardiac involvement with heart failure symptoms.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P7",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Cardiac involvement with heart failure symptoms.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P8",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Cardiac involvement with heart failure symptoms.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P9",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Cardiac involvement with heart failure symptoms.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P10",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Cardiac involvement with heart failure symptoms.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P11",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": "No symptoms of cardiac involvement.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P12",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": "No symptoms of cardiac involvement.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P13",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": "No symptoms of cardiac involvement.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        },
        {
          "individual_id": "P14",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": "No symptoms of cardiac involvement.",
          "evidence_sentence": "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
        }
      ],
      "functional_data": {
        "summary": "Tafamidis treatment showed subtle but statistically significant reductions in ECV, indicating a decrease in amyloid deposition.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families as indicated by the high percentage of affected individuals.",
      "population_frequency": null,
      "evidence_level": "high",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The study highlights the significant cardiac involvement in patients with the A97S variant.",
      "key_quotes": [
        "A substantial proportion, up to 82.1% of patients with hereditary A97S ATTR amyloidosis experience cardiac involvement."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "Data was extracted thoroughly from the main text, focusing on the TTR gene."
  }
}